Chemotherapy sensitivity testing on ovarian cancer cells isolated from malignant ascites
Metrics: PDF 233 views | Full Text 432 views | ?
Judith E. den Ouden1, Guido J.R. Zaman2, Jelle Dylus2, Antoon M. van Doornmalen2, Winfried R. Mulder2, Yvonne Grobben2, Wilhelmina E. van Riel2, Joanne A. de Hullu1, Rogier C. Buijsman2 and Anne M. van Altena1
1 Radboud Institute for Health Sciences, Radboud University Medical Center, Obstetrics and Gynecology, Nijmegen, The Netherlands
2 Netherlands Translational Research Center B.V., Oss, The Netherlands
|Anne M. van Altena,||email:||Anne.vanAltena@radboudumc.nl|
Keywords: ovarian cancer; chemotherapy sensitivity; prediction; ascites; proliferation assays
Received: April 08, 2020 Accepted: November 12, 2020 Published: December 08, 2020
Background: In epithelial ovarian cancer (EOC), 15–20% of the tumors do not respond to first-line chemotherapy (paclitaxel with platinum-based therapy), and in recurrences this number increases. Our aim is to determine the feasibility of cell proliferation assays of tumor cells isolated from malignant ascites to predict in vitro chemotherapy sensitivity, and to correlate these results with clinical outcome.
Materials and Methods: Ascites was collected from twenty women with advanced EOC. Cell samples were enriched for tumor cells and EOC origin was confirmed by intracellular staining of CK7, surface staining of CA125 and EpCAM, and HE4 gene expression. In vitro sensitivity to chemotherapy was determined in cell proliferation assays using intracellular ATP content as an indirect measure of cell number. In vitro drug response was quantified by calculation of the drug concentration at which cell growth was inhibited with 50%. Clinical outcome was determined using post-treatment CA125 level.
Results: Cell samples of twenty patients were collected, of which three samples that failed to proliferate were excluded in the analysis (15%). Three other samples were excluded, because clinical outcome could not be determined correctly. In twelve of the fourteen remaining cases (86%) in vitro drug sensitivity and clinical outcome corresponded, while in two samples (14%) there was no correspondence.
Conclusions: Our study demonstrates the feasibility of drug sensitivity tests using tumor cells isolated from ascites of advanced EOC patients. Larger observational studies are required to confirm the correlation between the in vitro sensitivity and clinical outcome.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.